StockData
Beam Therapeutics Inc. logo

Beam Therapeutics Inc. (BEAM) stock

BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)

Close on Nov 13, 2026Market cap $2.36BP/E –Yield –

Beam Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Beam Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -54.7%. For fiscal 2025 it was -57.2%, against -593.1% the year before. The highest annual figure on record is -35.1% in fiscal 2023.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-57.2%+535.9
FY2024Dec 31, 2024-593.1%−558.0
FY2023Dec 31, 2023-35.1%+439.5
FY2022Dec 31, 2022-474.5%+240.4
FY2021Dec 31, 2021-714.9%+810085.1
FY2020Dec 31, 2020-810800.0%−375655.6
FY2019Dec 31, 2019-435144.4%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-25036.3%−23829.9
Q1 FY2026Mar 31, 2026-297.2%+1153.0
Q4 FY2025Dec 31, 2025214.1%+514.6
Q3 FY2025Sep 30, 2025-1162.4%−484.9
Q2 FY2025Jun 30, 2025-1206.4%−433.0
Q1 FY2025Mar 31, 2025-1450.2%−118.6
Q4 FY2024Dec 31, 2024-300.5%−345.7
Q3 FY2024Sep 30, 2024-677.5%−118.6
Q2 FY2024Jun 30, 2024-773.5%−362.0
Q1 FY2024Mar 31, 2024-1331.6%−933.1
Q4 FY2023Dec 31, 202345.2%+236.6
Q3 FY2023Sep 30, 2023-558.9%+134.7
Q2 FY2023Jun 30, 2023-411.5%+20.6
Q1 FY2023Mar 31, 2023-398.5%+422.4
Q4 FY2022Dec 31, 2022-191.4%−64.7
Q3 FY2022Sep 30, 2022-693.6%+2991.6
Q2 FY2022Jun 30, 2022-432.1%+1270451.3
Q1 FY2022Mar 31, 2022-820.8%+3358512.5
Q4 FY2021Dec 31, 2021-126.7%+1590940.0
Q3 FY2021Sep 30, 2021-3685.2%+570514.8
Q2 FY2021Jun 30, 2021-1270883.3%−700583.3
Q1 FY2021Mar 31, 2021-3359333.3%−2851700.0
Q4 FY2020Dec 31, 2020-1591066.7%−1126900.0
Q3 FY2020Sep 30, 2020-574200.0%−257450.0
Q2 FY2020Jun 30, 2020-570300.0%−272616.7
Q1 FY2020Mar 31, 2020-507633.3%–
Q4 FY2019Dec 31, 2019-464166.7%–
Q3 FY2019Sep 30, 2019-316750.0%–
Q2 FY2019Jun 30, 2019-297683.3%–

More Beam Therapeutics figures

See a number that looks wrong?